在接受本拉利祖马布治疗的患有严重,不受控制的喘的eosinophilic患者中使用CompEx
Clare Bolton1, Tim Harrison1,2, Njira Lugogo3
1BioPharmaceuticals Medical, AstraZeneca, Cambridge, UK.
ERJ open research
|March 19, 2024
概括
在患有严重喘的患者中,本拉利祖马布有效降低了喘恶化,包括复合终点 (CompEx) 和严重恶化 (SevEx). 治疗效应在不同血液中异氨基酸细胞计数中一致,支持CompEx作为一个有价值的结果指标.
科学领域:
- 肺部病理学 肺部病理学
- 临床药理学 临床药理学
- 生物统计学 生物统计学
背景情况:
- 喘恶化是一个很大的负担,需要有效的治疗策略.
- 喘恶化复合终点 (CompEx) 整合了急性恶化事件 (AWE) 和严重恶化事件 (SevEx).
- 贝纳利祖马布向了带有异氨酸性炎症的严重喘.
研究的目的:
- 评估本拉利祖马布对严重喘患者的CompEx和SevEx的治疗效果.
- 为了评估血中乙氨基酸细胞数量与本拉利祖马布疗效之间的相关性.
- 验证CompEx作为严重喘临床试验中的相关终点.
主要方法:
- 来自两个第三阶段研究的12个月数据的后期分析.
- 包括16岁以上的患有严重,不受控制的喘的患者,随机分配给本拉利祖马布或安慰剂.
- 分析了使用负二项式模型的年化事件率,并评估了血中乙氨基酸细胞数量的影响.
主要成果:
- 贝纳利祖马布显著降低了CompEx,SevEx和AWE与安慰剂相比,在患有血中异氨基酸细胞计数≥300细胞/μL的患者中.
- 对CompEx和SevEx的风险比分分别为0.61和0.60 (p<0.001).
- 本拉利祖马布缩短了CompEx,SevEx和AWE的中位事件持续时间,在较高的乙氨基酸细胞数量时效果更大.
结论:
- 本拉利祖马布在严重喘中显示了对CompEx,SevEx和AWE的可比治疗效果.
- 该研究支持使用CompEx作为评估本拉利祖马布和类似疗法的有效终点.
- 班拉利祖马布的有效性与血液中乙氨基酸水平有关,加强了其向机制.
相关概念视频
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
294
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
294
01:19Antiasthma Drugs: Leukotriene Modifiers
297
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
297
01:24Asthma-III: Symptoms and Complications
2.5K
Asthma, a common chronic respiratory condition, is classified considering the frequency and severity of symptoms alongside lung function impairment. Understanding this classification is essential for appropriate treatment and management. Here's a detailed look at the classification of asthma and its clinical features and complications:
Classification of Asthma
Classification of Asthma
2.5K
01:25Antiasthma Drugs: β2-Adrenoceptor Agonists
264
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
264
01:30Asthma-IV: Diagnostic and Management
2.5K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.5K
01:25Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
245
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
245